Brought to you by 
Galena Biopharma reverse merges with Sellas Life Sciences
04 Sep 2020
Executive Summary
Cancer immunotherapy firms Galena Biopharma Inc. and privately held Sellas Life Sciences Group Ltd. agreed to an all-stock reverse merger in which Sellas will merge into Galena and become a wholly owned subsidiary. The combined company--to be named Sellas Life Science Group Inc.--will be 67.5% owned by Sellas and 32.5% by Galena, and will take over Galena’s Nasdaq stock listing under the new symbol SLS.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Stock
- Reverse Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Galena Biopharma reverse merges with Sellas Life Sciences
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice